Contineum Therapeutics reported topline results from its Phase 2 VISTA trial of PIPE‑307, an M1 receptor antagonist developed in partnership with Johnson & Johnson, and the study missed its primary and key secondary efficacy endpoints for vision outcomes in relapsing‑remitting multiple sclerosis (RRMS). The trial enrolled 182 patients and showed acceptable safety but no significant change in binocular low-contrast letter acuity across arms. Contineum’s shares fell sharply after the announcement. The company said it will analyze exploratory endpoints and present full data at a future medical forum; J&J retains a collaboration interest tied to the program.